P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Species Specificity of Amidine-Based Urokinase Inhibitors
Vered Klinghofer,Kent D. Stewart,Tom Mcgonigal,Richard S. Smith,Aparna V. Sarthy,Vicki L. Nienaber,Christopher C Butler,Sarah A. Dorwin,Paul G. Richardson,Moshe Weitzberg,Michael D. Wendt,Todd W. Rockway,Xumiao Zhao,K. I. Hulkower,Vincent L. Giranda +14 more
TL;DR: Inhibitors such as amiloride, B428, and naphthamidine, that occupy only the S1 subsite pocket were found to be nearly equipotent between the human and the murine enzymes, and compounds bearing a cationic group that interacts with residue 60 will preferentially bind to the human enzyme because of favorable electrostatic interactions.
Journal ArticleDOI
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
Paul Dowling,Paul Dowling,Catriona A. Hayes,Catriona A. Hayes,Kay Reen Ting,Kay Reen Ting,Abdul Hameed,Abdul Hameed,Justine Meiller,Constantine S. Mitsiades,Kenneth C. Anderson,Martin Clynes,Colin Clarke,Paul G. Richardson,Peter O'Gorman,Peter O'Gorman,Peter O'Gorman +16 more
TL;DR: Enzyme-linked immunosorbent assay of complement C4 and serum paraoxonase/arylesterase 1 indicated that these proteins were associated with high bone disease in a larger independent cohort of patient samples, indicating that these biomolecules may be clinically useful in assessing the extent of bone disease.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.
Paul G. Richardson,Sundar Jagannath,Noopur Raje,Andrzej Jakubowiak,Sagar Lonial,Irene Ghobrial,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,Kathleen Colson,Mary McKenney,Melissa Farrell,Laura E. Lunde,Lawrence Giove,Sarah Kaster,Constantine S. Mitsiades,Teru Hideshima,Robert Knight,Dixie-Lee Esseltine,Kenneth C. Anderson +19 more
TL;DR: RVD is very active in pts with relapsed and/or refractory MM, including pts with prior Rev, Vel, thalidomide, and SCT, including 1 DVT in the context of air travel in a pt who had been receiving aspirin 81mg as thromboprophylaxis.
Journal ArticleDOI
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
TL;DR: There is a clear need to derive a consensus that is useful for clinicians considering both protocol-directed and non-protocol-directed options for their patients, and preliminary randomized data from studies in Europe favor early ASCT with novel agents, suggest that one size does not fit all.
Journal ArticleDOI
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up
Paul G. Richardson,Sundar Jagannath,Andrzej Jakubowiak,Sagar Lonial,Noopur Raje,Melissa Alsina,Irene M. Ghobrial,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,David H. Vesole,Kathleen Colson,Mary McKenney,Laura E. Lunde,John Feather,Teru Hideshima,Robert Knight,Dixie-Lee Esseltine,Constantine S. Mitsiades,Kenneth C. Anderson +19 more
TL;DR: The aim of this prospective, multicenter, phase II study was to further evaluate the efficacy of RVD in pts with relapsed or relapsed/refractory MM at the MTD, and to present updated and mature data after >2 years9 follow up.